drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti-CD20 CAR T-cell therapy (also known as ELC-301) engineered to express and secrete Helicobacter pylori neutrophil-activating protein (HP-NAP) upon CD20 engagement, enabling direct killing of CD20+ B cells and recruitment/activation of innate immune cells to enhance anti-tumor immunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous anti-CD20 CAR T cells that directly kill CD20+ B cells; upon antigen engagement they secrete Helicobacter pylori neutrophil-activating protein (HP-NAP), recruiting and activating innate immune cells (e.g., neutrophils, monocytes/dendritic cells) and promoting Th1/NK responses to enhance bystander anti-tumor immunity.
drug_name
CAR20(NAP)-T
nct_id_drug_ref
NCT06002659